La vendita allo scoperto per Ocean Biomedical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Ocean Biomedical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Ocean Biomedical (NASDAQ:OCEA) Azioni, Report sulle vendite allo scoperto

Ocean Biomedical

Ocean Biomedical Inc is a biopharmaceutical company. It is dedicated towards partnering with inventor-scientists and research institutes to bridge the gap between basic research and clinical development, to get new medicines to the patients who need it most.

Ocean Biomedical Inc

Ocean Protocol - United States Dollar

OCEAN WILSONS ORD

OCEANEERING INTERNATIONAL ORD

Ocean Capital Acquisition Corp

Ocean Capital Acquisition Corporation

Ocean Drive Acquisition Corp

Ocean Park High Income ETF

Ocean Park International ETF

Ocean Power Technologies, Inc. Common Stock

Ocean Power Technologies Inc

OCEAN SPRAY 4 PR by Ocean Spray Cranberries, Inc.

Ocean Spray Cranberries Inc

OCEAN THERMAL ENERGY CORP by Ocean Thermal Energy Corp.

Ocean Thermal Energy Corp

OceanFirst Financial Corp. - Common Stock

OceanFirst Financial Corp

OceanFirst Financial Corp. - Depositary Shares

OceanPal Inc

OceanTech Acquisitions I Corp Units (1 Ord Class A & 1 War)

OceanTech Acquisitions I Corp

OceanTech Acquisitions I Corp Warrants (12/05/2026)

OceanTech Acquisitions I Corp Class A

Oceana Group Ltd

OceanaGold Corp

OCEANAGOLD (PHILIPPINES) by OCEANAGOLD (PHILIPPINES) INC.

OceanaGold Philippines Inc

Oceaneering International, Inc. Common Stock

Oceaneering International Inc

OCEANIA HEALTHCARE LTD by Oceania Healthcare Ltd.

Oceania Healthcare Ltd

OCEANIC IRON ORE CORP NEW by Oceanic Iron Ore Corp.

Oceanic Iron Ore Corp

OCEANIC WIND ENERGY INC. by Oceanic Wind Energy Inc.

Oceanic Wind Energy Inc

OCEANSIX FUTURE PATHS LTD by OCEANSIX FUTURE PATHS LTD.

Oceansix Future Paths Ltd

<a href="https://thebearcave.substack.com/p/problems-at-viasat-vsat" title="https://thebearcave.substack.com/p/problems-at-viasat-vsat">https://thebearcave.substack.com/p/problems-at-viasat-vsat</a>

VSAT

Watching Viasat; The Bear Cave Newsletter Issues Report Titled 'Problems at Viasat (VSAT)'

Susquehanna analyst Christopher Rolland maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Neutral and lowers the price target from $260 to $250.

News

Price Target

Analyst Ratings

NXPI

Susquehanna Maintains Neutral on NXP Semiconductors, Lowers Price Target to $250

Wells Fargo analyst Jason Haas maintains Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) with a Underweight and raises the price target from $460 to $470.

Wells Fargo Maintains Underweight on Gartner, Raises Price Target to $470

Susquehanna analyst Christopher Rolland maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Positive and lowers the price target from $95 to $90.

MCHP

Susquehanna Maintains Positive on Microchip Technology, Lowers Price Target to $90

Financial giants have made a conspicuous bearish move on Freeport-McMoRan. Our analysis of options history for Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) revealed 16 unusual trades.
Delving into the details, we found 31% of traders were bullish, while 56% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $57,912, and 14 were calls, valued at $1,995,172.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $33.0 and $50.0 for Freeport-McMoRan, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Freeport-McMoRan's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Freeport-McMoRan's whale activity within a strike price range from $33.0 to $50.0 in the last 30 days. 
<h3>Freeport-McMoRan Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907075_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.6</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$50.00</td>
<td>$520.3K</td>
<td>35.4K</td>
<td>5.1K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.54</td>
<td>$1.43</td>
<td>$1.5</td>
<td>$50.00</td>
<td>$506.2K</td>
<td>35.4K</td>
<td>10.7K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$1.54</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$50.00</td>
<td>$204.1K</td>
<td>35.4K</td>
<td>5.1K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.49</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$50.00</td>
<td>$139.3K</td>
<td>35.4K</td>
<td>7.4K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.45</td>
<td>$1.43</td>
<td>$1.43</td>
<td>$50.00</td>
<td>$98.6K</td>
<td>35.4K</td>
<td>6.4K</td>
</tr>
</tbody>
</table>

<h3>About Freeport-McMoRan</h3>
Freeport-McMoRan Inc is an international mining company. It has organized its mining operations into four primary divisions: North America copper mines, South America mining, Indonesia mining and Molybdenum mines. Its reportable segments include the Morenci, Cerro Verde and Grasberg (Indonesia mining) copper mines, the Rod &amp; Refining operations and Atlantic Copper Smelting and Refining. It derives key revenue from the sale of Copper.
After a thorough review of the options trading surrounding Freeport-McMoRan, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Freeport-McMoRan's Current Market Status</h3>
<ul>
<li>With a volume of 3,545,458, the price of FCX is down -2.09% at $46.01. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for Freeport-McMoRan</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $54.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Raymond James keeps a Outperform rating on Freeport-McMoRan with a target price of $57. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Perform rating on Freeport-McMoRan, which currently sits at a price target of $53. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Freeport-McMoRan, targeting a price of $52. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Freeport-McMoRan, targeting a price of $55. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Freeport-McMoRan, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

This Is What Whales Are Betting On Freeport-McMoRan

Financial giants have made a conspicuous bullish move on Mastercard. Our analysis of options history for Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $98,538, and 7 were calls, valued at $507,653.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $390.0 to $530.0 for Mastercard during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Mastercard stands at 232.62, with a total volume reaching 226.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Mastercard, situated within the strike price corridor from $390.0 to $530.0, throughout the last 30 days.
<h3>Mastercard Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907070_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$124.65</td>
<td>$121.65</td>
<td>$123.99</td>
<td>$400.00</td>
<td>$99.1K</td>
<td style="text-align: right;">487</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$133.4</td>
<td>$129.0</td>
<td>$129.0</td>
<td>$420.00</td>
<td>$90.4K</td>
<td style="text-align: right;">183</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$155.85</td>
<td>$153.5</td>
<td>$153.55</td>
<td>$390.00</td>
<td>$76.7K</td>
<td style="text-align: right;">33</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$150.35</td>
<td>$145.25</td>
<td>$145.25</td>
<td>$400.00</td>
<td>$72.6K</td>
<td style="text-align: right;">198</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$7.05</td>
<td>$6.9</td>
<td>$7.05</td>
<td>$520.00</td>
<td>$70.6K</td>
<td style="text-align: right;">801</td>
<td style="text-align: right;">98</td>
</tr>
</tbody>
</table>

<h3>About Mastercard</h3>
Mastercard is the second-largest payment processor in the world, having processed close to over $9 trillion in volume during 2023. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
<h3>Current Position of Mastercard</h3>
<ul>
<li>With a volume of 778,613, the price of MA is up 2.7% at $519.19. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 84 days.</li>
</ul>
<h3>Professional Analyst Ratings for Mastercard</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $565.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Macquarie keeps a Outperform rating on Mastercard with a target price of $565. 
&#x2A; An analyst from Keybanc persists with their Overweight rating on Mastercard, maintaining a target price of $580. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Mastercard, maintaining a target price of $544. 
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Mastercard, targeting a price of $605. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Mastercard, targeting a price of $532. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Mastercard with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Mastercard Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $214,735, and 7 are calls, for a total amount of $478,040.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $130.0 for Moderna over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Moderna's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $40.0 to $130.0 in the last 30 days. 
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907065_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1.31</td>
<td>$1.27</td>
<td>$1.31</td>
<td>$60.00</td>
<td>$107.5K</td>
<td>2.9K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.55</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$50.00</td>
<td>$105.8K</td>
<td>4.7K</td>
<td>513</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$16.7</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$88.2K</td>
<td>40</td>
<td>150</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.0</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$78.2K</td>
<td>40</td>
<td>97</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.4</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$73.2K</td>
<td>40</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,021,467, with MRNA's price down by -1.31%, positioned at $52.59.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $69.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein has revised its rating downward to Market Perform, adjusting the price target to $55. 
&#x2A; An analyst from UBS persists with their Buy rating on Moderna, maintaining a target price of $108. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $59. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on Moderna with a target price of $55. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

MRNA

Moderna Options Trading: A Deep Dive into Market Sentiment

<a href="https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html" title="https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html">https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html</a>

PLNT

'Planet Fitness wants to acquire bankrupt budget-fitness chain Blink Holdings' - CNBC

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories 0.412M Barrel Build Vs 1.650M Barrel Draw Est.; 2.707M Barrel Draw Prior

EIA Weekly Distillates Stocks 2.947M Barrel Build Vs 1.500M Barrel Draw Est.; 0.977M Barrel Draw Prior

Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) has outperformed the market over the past 5 years by 15.97% on an annualized basis producing an average annual return of 29.67%. Currently, Iron Mountain has a market capitalization of $37.08 billion. 
Buying $100 In IRM: If an investor had bought $100 of IRM stock 5 years ago, it would be worth $364.41 today based on a price of $126.40 for IRM at the time of writing.
<h3>Iron Mountain's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907021_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Iron Mountain 5 Years Ago Would Be Worth This Much Today

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) has outperformed the market over the past 5 years by 6.16% on an annualized basis producing an average annual return of 19.86%. Currently, Williams Companies has a market capitalization of $66.91 billion. 
Buying $1000 In WMB: If an investor had bought $1000 of WMB stock 5 years ago, it would be worth $2,469.20 today based on a price of $53.05 for WMB at the time of writing.
<h3>Williams Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

Wells Fargo analyst Brandon Couillard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $78 to $75.

BRKR

Wells Fargo Maintains Overweight on Bruker, Lowers Price Target to $75

Macro Notification

General

USA Crude Oil Inventories 2.149M Barrel Build Vs 0.300M Barrel Build Est.; 0.515M Barrel Draw Prior

Susquehanna analyst Mehdi Hosseini maintains GLOBALFOUNDRIES (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) with a Neutral and lowers the price target from $50 to $48.

Susquehanna Maintains Neutral on GLOBALFOUNDRIES, Lowers Price Target to $48

RBC Capital analyst Jimmy Shan maintains Colliers Intl Gr (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CIGI#TSX">CIGI</a>) with a Outperform and lowers the price target from C$174 to C$170.

CIGI

TSX:CIGI

RBC Capital Maintains Outperform on Colliers Intl Gr, Lowers Price Target to C$170

Wells Fargo analyst Vik Chopra maintains Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) with a Overweight and raises the price target from $78 to $88.

GMED

Wells Fargo Maintains Overweight on Globus Medical, Raises Price Target to $88

RBC Capital analyst Maurice Choy reiterates Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Sector Perform and maintains C$65 price target.

Reiteration

TSX:FTS

RBC Capital Reiterates Sector Perform on Fortis, Maintains C$65 Price Target

Wells Fargo analyst Vik Chopra maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Overweight and raises the price target from $160 to $171.

MASI

Wells Fargo Maintains Overweight on Masimo, Raises Price Target to $171

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 1,200 points on Wednesday.
The Dow traded up 2.90% to 43,445.79 while the NASDAQ rose 2.03% to 18,813.03. The S&amp;P 500 also rose, gaining, 1.77% to 5,884.97.
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/11/41774936/how-to-earn-500-a-month-from-qualcomm-stock-ahead-of-q4-earnings">How To Earn $500 A Month From Qualcomm Stock Ahead Of Q4 Earnings</a>
Leading and Lagging Sectors Financial shares surged by 4.4% on Tuesday.
In trading on Tuesday, real estate shares fell by 1.8%.
Top Headline
Former President Donald Trump declared victory in the 2024 presidential election after winning the key battleground states.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>FOXO Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NASDAQ">FOXO</a>) shares shot up 171% to $0.3718.</li>
<li>Shares of Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) got a boost, surging 110% to $8.82 after the company announced the issuance of a U.S. patent covering an IL-18 variant into two novel immunotherapeutic drug candidates.</li>
<li>Trilogy Metals Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMQ#NYSE">TMQ</a>) shares were also up, gaining 73% to $0.9835.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) shares dropped 42% to $4.12.</li>
<li>Shares of Zoomcar Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCAR#NASDAQ">ZCAR</a>) were down 40% to $7.94 after the company announced the pricing of $9.15 million private placement.</li>
<li>PACS Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) was down, falling 35% to $19.14 after the company announced postponement of third-quarter results and disclosure on civil investigative demands from the federal government.</li>
</ul>
Commodities In commodity news, oil traded down 0.7% to $71.50 while gold traded down 2.8% at $2,672.20.
Silver traded down 4.8% to $31.215 on Wednesday, while copper fell 4.6% to $4.2690.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 fell 0.6%, Germany's DAX dipped 1.2% and France's CAC 40 fell 0.8%. Spain's IBEX 35 Index fell 3.1%, while London's FTSE 100 fell 0.3%.
Asia Pacific Markets
Asian markets closed mixed on Wednesday, with Japan's Nikkei 225 gaining 2.61%, Hong Kong's Hang Seng Index falling 2.23%, China's Shanghai Composite Index falling 0.09% and India's BSE Sensex gaining 1.13%.
Economics
U.S. mortgage applications fell by 10.8% from the previous week in the week ended Nov. 1.
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41773566/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-3-dividend-yie">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>

Earnings

Equities

Eurozone

Commodities

Intraday Update

FOXO

NOVA

PACS

SONN

ZCAR

Dow Jumps Over 1,200 Points; Donald Trump Wins White House

At least that is what the poet T.S. Eliot wrote in the opening line of his well-known poem, "The Wasteland". With all the chatter about an April correction it might be, but traditionally April is one of the strongest months for the stock market.

Tuesday Talk: April Is The Cruelest Month?

The latest update is out from Ocean Biomedical (OCEA). Ocean Biomedical, Inc. has delayed its annual financial report and received a notice from Na...

Ocean Biomedical Faces Compliance Challenges and Delays Report

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Ocean Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocea-stock-quote/">OCEA</a>) just reported results for the third quarter of 2023.<ul><li>Ocean Biomedical reported earnings per share of -53 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ocea-stock-earnings-ocean-biomedical-for-q3-of-2023/">OCEA Stock Earnings: Ocean Biomedical Reported Results for Q3 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OCEA Stock Earnings: Ocean Biomedical Reported Results for Q3 2023

Ocean Biomedical gets non-compliance notice from Nasdaq

An update from Ocean Biomedical (OCEA) is now available. Ocean Biomedical, Inc. has delayed its quarterly report filing, leading to a notice from N...

Ocean Biomedical Faces Nasdaq Non-Compliance Notice and Delays

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out as we dive into all of the biggest news sending shares higher and lower on Wednesday morning!



Moving stocks this morning are delisting notices, an acquisition plan, a public share offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Sify Technologies Limited &ndash; Rights (NASDAQ:<a href="https://investorplace.com/stock-quotes/sifyr-stock-quote/">SIFYR</a>) are rocketing more than 49% <a href="https://www.nasdaq.com/articles/sify-technologies-sets-ads-rights-delisting-date">ahead of their delisting next week</a>.</li>



<li>Golden Heaven (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdhg-stock-quote/">GDHG</a>) stock is soaring over 47% with heavy pre-market trading.</li>



<li>Wang &amp; Lee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wlgs-stock-quote/">WLGS</a>) shares are surging close to 40% with strong early morning trading.</li>



<li>Singing Machine (NASDAQ:<a href="https://investorplace.com/stock-quotes/mics-stock-quote/">MICS</a>) stock is gaining more than 29% <a href="https://www.nasdaq.com/press-release/singing-machine-acquire-semicab-leading-ai-logistics-technology-company-2024-06-12">on acquisition news</a>.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) shares are increasing nearly 25% this morning.</li>



<li>Beamr Imaging (NASDAQ:<a href="https://investorplace.com/stock-quotes/bmr-stock-quote/">BMR</a>) stock is rising over 23% after <a href="https://seekingalpha.com/news/4115034-beamr-imaging-product-now-on-oracle-cloud-marketplace-shares-jump-30?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain%7Csection%3Aon-the-move">adding its product</a> to a new marketplace.</li>



<li>Molecular Partners (NASDAQ:<a href="https://investorplace.com/stock-quotes/moln-stock-quote/">MOLN</a>) shares are climbing more than 16% as they continue to rise on <a href="https://www.nasdaq.com/press-release/molecular-partners-and-orano-med-share-positive-preclinical-data-their-dll3-0">positive preclinical data</a>.</li>



<li>Surf Air Mobility (NYSE:<a href="https://investorplace.com/stock-quotes/srfm-stock-quote/">SRFM</a>) stock is jumping over 15% on Wednesday morning.</li>



<li>Ocean Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/ocea-stock-quote/">OCEA</a>) shares are heading 15% higher this morning.</li>



<li>NovaBay Pharmaceuticals (NYSEMKT:<a href="https://investorplace.com/stock-quotes/nby-stock-quote/">NBY</a>) stock is up more than 12% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>ThermoGenesis (NASDAQ:<a href="https://investorplace.com/stock-quotes/thmo-stock-quote/">THMO</a>) stock is plummeting over 41% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318387950&amp;type=PDF&amp;symbol=THMO&amp;cdn=c35080a0c43a3214912906647bd85f4c&amp;companyName=ThermoGenesis+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-11">on a delisting notice</a>.</li>



<li>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/">TNXP</a>) shares are diving almost 32% on a <a href="https://www.nasdaq.com/press-release/tonix-pharmaceuticals-announces-proposed-public-offering-2024-06-11">proposed public offering</a>.</li>



<li>U-BX Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/ubxg-stock-quote/">UBXG</a>) stock is tumbling more than 26% after rallying yesterday.</li>



<li>Clene (NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/">CLNN</a>) shares are taking an over 24% beating on Wednesday morning.</li>



<li>KWESST Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is sliding more than 22% <a href="https://investorplace.com/2024/06/why-is-kwesst-micro-systems-kwe-stock-up-121-today/">after rallying yesterday</a>.</li>



<li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) shares are retreating over 19% <a href="https://investorplace.com/2024/06/why-is-nauticus-robotics-kitt-stock-up-59-today/">after yesterday&rsquo;s rally</a>.</li>



<li>Blue World Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/bwaq-stock-quote/">BWAQ</a>) stock is falling more than 17% after rising higher yesterday.</li>



<li>Chanson International (NASDAQ:<a href="https://investorplace.com/stock-quotes/chsn-stock-quote/">CHSN</a>) shares are dropping over 16% this morning.</li>



<li>Mercurity Fintech (NASDAQ:<a href="https://investorplace.com/stock-quotes/mfh-stock-quote/">MFH</a>) stock is slipping more than 13% today.</li>



<li>Oblong (NASDAQ:<a href="https://investorplace.com/stock-quotes/oblg-stock-quote/">OBLG</a>) shares close out our pre-market stock movers down over 13%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Ocean Biomedical receives non-compliance notice from Nasdaq

Ocean Biomedical (OCEA) just unveiled an update. Ocean Biomedical has been notified by Nasdaq of non-compliance due to its failure to file the mand...

Ocean Biomedical Faces Nasdaq Compliance Challenges

Ocean Biomedical (OCEA) announced that it received a letter from Nasdaq stating that on April 18, May 22 and August 19, staff notified the company ...

Ocean Biomedical receives noncompliance letter from Nasdaq

Ocean Biomedical receives Nasdaq's delisting letter

BWAQ

CHSN

CLNN

GDHG

KITT

MICS

MOLN

OBLG

OCEA

SIFYR

SOUN

SRFM

THMO

TNXP

TSLA

UBXG

VKTX

WLGS

Press Releases

Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease

Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company's Malaria Treatment and Prevention Platforms

Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Publication of New Data Deepening Understanding of Novel Cancer Immunotherapy Treatment Approach Targeting CHI3L1 and its Ability to Inhibit Anti-tumor and Related Tissue Remodeling Responses

Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors.

Comments

Ocean Biomedical

Vendite allo scoperto

Ocean Biomedical (NASDAQ:OCEA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO